Company intelligence / Profile preview
CorreGene
Beijing, Beijing, Chinacorregene.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Two Investigator Initiated Trials launched. CRTE7A2 is in Phase I clinical trial targeting HPV16-positive advanced solid tumors including anal cancer. The company has reported improved success rates using its proprietary SMART-TCR technology to optimize affinity of therapeutic receptors.
- Therapeutic areas
- OncologyImmunologyInfectious Diseases
- Modalities
- TCR-T cell therapiesSoluble TCR-fusion proteinsBispecific TCR therapiesGenetically engineered T cells
- Industry
- Biotech
02
Drug pipeline
15 assets14 more assets in the full pipeline.
03
Partnerships
Shenzhen Eureka Biotechnology Co., Ltd.
Beyond the preview
Go deeper on CorreGene.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CorreGene.